Naphthoquinone Derivatives as Scaffold to Develop New Drugs for Tuberculosis Treatment

Priscila C. B. Halicki¹, Lais A. Ferreira¹, Kelly C. G. De Moura², Paula F. Carneiro², Karina P. Del Rio², Tatiane dos S. C. Carvalho², Maria do C. F. R. Pinto², Pedro E. A. da Silva¹ and Daniela F. Ramos¹*

¹ Núcleo de Pesquisa em Microbiologia Médica, Faculdade de Medicina, Universidade Federal do Rio Grande, Rio Grande, Brazil, ² Núcleo de Pesquisas em Produtos Naturais, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

Despite being a curable disease, tuberculosis (TB) remains a public health problem worldwide mainly due to lengthy treatment, as well as its toxic effects, TB/HIV co-infection and the emergence of resistant *Mycobacterium tuberculosis* strains. These barriers reinforcing the need for development of new antimicrobial agents, that ideally should reduce the time of treatment and be active against susceptible and resistant strains. Quinones are compounds found in natural sources and among them, the naphthoquinones show antifungal, antiparasitic, and antimycobacterial activity. Thus, we evaluated the potential antimycobacterial activity of six 1,4-naphthoquinones derivatives. We determined the minimum inhibitory concentration (MIC) of the compounds against three *M. tuberculosis* strains: a pan-susceptible H37Rv (ATCC 27294); one mono-resistant to isoniazid (ATCC 35822); and one mono-resistant to rifampicin (ATCC 35838); the cytotoxicity in the J774A.1 (ATCC TIB-67) macrophage lineage; performed in silico analysis about absorption, distribution, metabolism, and excretion (ADME) and docking sites. All evaluated naphthoquinones were active against the three strains with MIC between 206.6 and 12.5 µM, and the compounds with lower MIC values have also showed low cytotoxicity. Moreover, two naphthoquinones derivatives 5 and 6 probably do not exhibit cross resistance with isoniazid and rifampicin, respectively, and regarding ADME analysis, no compound violated the Lipinski’s rule-of-five. Considering the set of findings in this study, we conclude that these naphthoquinones could be promising scaffolds to develop new therapeutic strategies to TB.

Keywords: *Mycobacterium tuberculosis*, naphthoquinones, antimicrobials, resistance, tuberculosis

INTRODUCTION

According to World Health Organization, tuberculosis (TB) is one of the top 10 causes of death worldwide and, in 2016, there were an estimated the incidence of 10.4 million new cases (WHO, 2017). The main strategies for reducing TB morbidity and mortality rates are related to prophylaxis, early diagnosis and effective treatment of the disease. Bacille Calmette–Guérin (BCG) vaccine has been administered since the beginning of the 20th century in the immunization process, but only
protects against the most severe cases of TB (Andersen and Woodworth, 2014; Stefanova, 2014). Despite the technological advances in the diagnostic area and the absence of an effective vaccine, the therapy still is the main tool for TB control.

The first-line therapy regimen for TB is a combination of four drugs: isoniazid (INH), rifampicin (RIF), pyrazinamide and ethambutol, which cure about 85% of patients infected with susceptible strains (WHO, 2017). Other antimicrobials such as kanamycin, amikacin, capreomycin, ethionamide, and levofloxacin are considered second-line drugs. These drugs are also used in the treatment of TB, especially in cases of multidrug-resistant strains (MDR) infection – which are resistant to both INH and RIF – and when there is intolerance to first-line drugs. However, second-line therapy is more expensive, more toxic, and less effective than basic therapy (Ma et al., 2010).

Over the past 15 years, the TB treatment was able to avoid at least 50 million deaths, however, there is still a gap in this regard (WHO, 2017). Although it is a curable disease, there are several factors that hamper the TB control: lengthy treatment, toxic effects, pharmacokinetic interactions with other drugs, TB-HIV co-infection and the emergence of drug resistance (Palomino et al., 2009). Still in this context, the available therapeutic arsenal is insufficient, being ineffective against resistant strains and latent TB (Ma et al., 2010). Thus, new antimicrobial agents with novel mechanisms of action could be effective in the management of TB, reducing cross-resistance, the length of treatment and the adverse effects. It would increase the patient compliance to the therapy, favoring the cure (Hoagland et al., 2016; Igarashi et al., 2017).

The natural sources have been highlighted in the discovery and development of new antibiotics mainly due to structural diversity of the compounds, therapeutic potential and plethoric mechanisms of action (Bérdy, 2012; Newman and Cragg, 2016). Among the compounds that may be found in a variety of plants, algae, bacteria and fungi, are quinones: aromatic compounds which are classified in anthraquinones, benzoquinones and naphthoquinones, according to their chemical compositions (López-López et al., 2014). The naphthoquinones and derivatives have a naphthalene ring, and some studies have reported its antibacterial, antitumoral, antileishmanial, anthelmintic, and antifungal activity (Coelho et al., 2010; Hazra et al., 2013; Fiorito et al., 2014; Neto et al., 2014; Mata-Santos et al., 2015). Some mechanisms of action have been proposed for naphthoquinones, mainly related to oxidative stress – due to the production of reactive oxygen species (ROS) which induce apoptosis in biological systems (Da Silva et al., 2003) – and to inhibition of DNA gyrase (Karkare et al., 2013).

Previous research has demonstrated the antimycobacterial activity of naphthoquinones (Mital et al., 2008; Coelho et al., 2010; Ferreira et al., 2010; Cantos et al., 2012; Uc-Cachón et al., 2014), including against multidrug and extensively drug resistant strains (Dey et al., 2014), bringing attention to the potential of these compounds as a basis for the development of new anti-TB drugs. In this scenario, we aimed to evaluate the antimycobacterial activity of six 1,4-naphthoquinones derivatives against susceptible and drug resistant strains of Mycobacterium tuberculosis.

MATERIALS AND METHODS

Synthesis

The naphthoquinone 1 is commercial, and the other compounds were synthesized using methods previously described in the literature. Naphthoquinones 2 and 3 were synthesized via cyclization of lapachol and nor-lapachol, respectively (De Moura et al., 2001), while naphthoquinone 4 was synthesized via lawsone amination in a two steps procedure (Pinto et al., 1997). The amination of 1,4-naphthoquinone with sodium azide resulted in the naphthoquinone 5 (Fieser and Hartwell, 1935) while the amination with aniline resulted in the naphthoquinone 6 (Lisboa et al., 2011) (Table 1). All compounds were solubilized in dimethyl sulfoxide 99.5% (Sigma-Aldrich) at a concentration of 10 mg/ml and stored at 4°C until used.

Strains and Inoculum

The antimicrobial activity of naphthoquinones was evaluated against three strains of M. tuberculosis: a pan-susceptible, H37Rv (ATCC 27294); a mono-resistant to INH (INHR – ATCC 35822) with mutation in the katG gene (S315T); and a mono-resistant to RIF (RMP – ATCC 35838) with mutation in rpoB gene (H526Y). All strains were cultured in Ogawa-Kudoh, for up to 14 days at 37°C without CO2. The inoculum for each strain was prepared in a glass tube containing beads to break the
clumps, in sterile distilled water, according to 1.0 McFarland scale (3 × 10^5 UFC/mL) (Woods et al., 2011). After this process, it was diluted at a ratio of 1:20 in Middlebrook 7H9 Broth. The tests were performed at the Medical Microbiology Research Center (NUPEMM), at the Federal University of Rio Grande (FURG), under strict conditions required for handling M. tuberculosis.

**Resazurin Microtiter Assay (REMA)**
The minimum inhibitory concentration (MIC) of the compounds was determined by Resazurin Microtiter Assay (Palomino et al., 2002). Briefly, in a 96-well microplate, 100 µl of 7H9 medium supplemented with 10% OADC (Oleic acid Albumin Dextrose Catalase) was added in the test wells. In the first line was added 100 µl of the last well was discarded. At the end of microdilution was added 100 µl of inoculum in each well and the final range of concentrations evaluated was 200 to 0.8 µg/mL for naphthoquinones, 8 to 0.03 µg/mL after, 100 µl a serial microdilution (1:2) was performed in the x-axis and, 100 µl of each compound was added in the test wells. In the first line was added 100 µl of each compound previously diluted in sterile water; a serial microdilution (1:2) was performed in the x-axis and, after, 100 µl of the last well was discarded. At the end of microdilution was added 100 µl of inoculum in each well and the final range of concentrations evaluated was 200 to 0.8 µg/mL for naphthoquinones, 8 to 0.03 µg/mL for INH and 1.024 to 0.06 µg/mL for RIF. In each plate were added sterility and growth controls. After incubation at 37°C for 7 days was added 30 µL of resazurin 0.02% on the plate and then, 24 h later, the reading of the results was performed. MIC was defined as the lowest concentration of compound capable of inhibiting bacterial growth. All tests were performed in triplicate.

**Cytotoxicity Assay**
The cytotoxicity of the compounds was evaluated on adherent J774A.1 macrophage cell line (ATCC TIB-67). In a 96-well plate, 200 µL of cell suspension (at the concentration of 1 × 10^5 cells/mL) were cultivated in Dulbecco’s modified Eagle medium (Sigma-Aldrich) supplemented with 10% of fetal bovine serum and maintained for 24 h at 37°C in a humid atmosphere with 5% CO₂ (Sewin et al., 1999). After this period, the attached cells were exposed to different concentrations of naphthoquinones (200 to 0.8 µg/mL) and the plate was again incubated overnight. To determine the cytotoxicity of the compounds capable of maintaining the viability of 50% of the cells (IC₅₀) were added 30 µL of resazurin 0.01% and after 24 h of incubation the fluorescence was measured by Thermo Plate TP-Reader BioTek™ ELx800™ (Ansar Ahmed et al., 1994).

**Selectivity Index (SI)**
The SI of the compounds was calculated based on the results of MIC and IC₅₀ of each compound for each strain, according to the following formula: IC₅₀/MIC. SI values equal to or greater than 10 indicate that the compound is pharmacologically safe (Orme, 2001; Pavan et al., 2012).

**Theoretical Properties of Absorption, Distribution, Metabolism, and Excretion (ADME)**
Characteristics of theoretical absorption, distribution, metabolism, and excretion (ADME) and toxicological effects of the compounds were determined by in silico analysis, using the free software: Molinspiration¹, Swiss ADME² (Daina et al., 2017), and OSIRIS Property Explorer³. According to the Lipinski Rule-of-Five, the following physicochemical parameters were evaluated: molecular weight, logP, H-bond donors, and H-bond acceptors (Lipinski, 2004).

**Docking Analysis**
Flexible docking simulation was performed by ArgusLab 4.0.1, using Escherichia coli RNA polymerase as a protein template. The structures were from Protein Data Bank (PDB)⁴ – files 5UAC and 5UAQ. The interaction between proteins (wild-type and mutant H526Y) and the ligands (RMP and compound 6) was evaluated from residues 507 to 533, which comprise the RMP resistance-determining region (RRDR) (Ramaswamy and Musser, 1998). In the docking calculations, it was applied the Ascore as scoring method (Luo et al., 2012).

**RESULTS**
All naphthoquinones showed inhibitory activity against the three M. tuberculosis strains with MIC ranging between 206.6 and 12.5 µM (Table 2). Besides the naphthoquinones being active against the susceptible strain, the compounds also showed various levels of activity against the resistant strains (Table 2). The compounds 1 and 3 showed, respectively, MIC = 110.6 and 54.8 µM, for all strains evaluated, while naphthoquinones 2 and 4 showed lower inhibitory concentrations against the susceptible strain, compared to the resistant strains. In addition, compounds 1, 2, and 4 exhibited IC₅₀ between 103 and 285 µM, resulting in SI values between 0.07 and 2.8.

For the INH₉R strain, compared with the H37Rv, all compounds showed equal or reduced activity, except for compound 5. On the other hand, in comparison with the RMP₉ strain, the only difference in MIC was related to the compound 6. Interestingly, the compound 6 was the most active against RMP₉ strain (MIC = 12.5 µM), in a concentration eight times less than the concentration capable of inhibiting the growth of H37Rv and INH₉R strains (MIC = 110.4 µM).

The compound 6 was able to inhibit RMP₉ strain (MIC = 12.5 µM) at a concentration 50x lower than the drug RMP (MIC = 622.2 µM) and, considering the peculiarity of this strain – which differs from the H37Rv mainly by the mutation in the rpoB gene (H526Y) – we were prompted to explore a possible affinity of this compound with mutant rpoB. By preliminary docking, we observed a reduction in the affinity between RMP and the RRDR site in mutant rpoB target (Figure 1A) while compound 6 showed more negative free energy – strong binding (Silva et al., 2017) – compared to RMP for both wild-type as well as the mutant protein (Figure 1).

Regarding the ADME analysis, all the naphthoquinones evaluated in this study showed high gastrointestinal

---

¹ molinspiration.com/cgi-bin/properties
² http://www.swissadme.ch/index.php
³ www.organic-adme.org/prog/peo/
⁴ https://www.rcsb.org
### Table 2: Activity of naphthoquinones against three M. tuberculosis strains and IC\textsubscript{50} on J774A.1 cells lineage.

| Compound | MIC (µM) | IC\textsubscript{50} (µM) | SI (IC\textsubscript{50}/MIC) |
|----------|----------|-----------------|-----------------|
|          | H37Rv    | INH\textsubscript{R} | RMP\textsubscript{R} | J774A.1 | H37Rv | INH\textsubscript{R} | RMP\textsubscript{R} |
| 1        | 110.6    | 110.6           | 110.6           | 103     | 0.9   | 0.9               | 0.9               |
| 2        | 103.3    | 206.6           | 206.6           | 285     | 2.8   | 1.4               | 1.4               |
| 3        | 54.8     | 54.8            | 54.8            | >877    | ≥16   | ≥16              | ≥16              |
| 4        | 58.4     | 234             | 234             | 173     | 0.3   | 0.07             | 0.07             |
| 5        | 72.2     | 36.1            | 36.1            | >1156   | ≥16   | ≥32              | ≥32              |
| 6        | 100.4    | 100.4           | 12.5            | >803    | ≥8    | ≥8               | ≥64              |
| INH      | 0.438    | 14.6            | <0.219          | 3733    | 8523  | 256              | ND               |
| RIF      | 0.608    | 0.304           | 622.2           | >2489   | ≥4094 | ≥8187            | ≥4               |

MIC, minimum inhibitory concentration; IC\textsubscript{50}, inhibitory concentration of 50%; SI, Selectivity Index; INH\textsubscript{R}, ATCC 35822; RMP\textsubscript{R}, ATCC 35838; ND, not determined.

In this study, by the pharmacokinetic analysis using the Software Swiss ADME, the theoretical inhibitory activity of naphthoquinone derivatives against five cytochrome P450 isoforms was evaluated (CYP450): CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. All compounds showed potential inhibitory activity of CYP1A2 and CYP2C19 isoforms, except for compound 5, which showed interaction only with CYP1A2.

In addition, most of the compounds showed none or low toxicity risk related to mutagenicity or tumorigenicity (Table 3).

![Figure 1](image-url)
In addition, compounds 2 and 6 also showed activity against the 3A4 isofrom.

**DISCUSSION**

We evaluated the antmycobacterial potential of six 1,4-naphthoquinone derivatives: all compounds were active against susceptible and resistant strains of *M. tuberculosis*, with different MIC values. Mathew et al. (2010) reported the antmycobacterial activity of plumbagin and its derivatives, and Dey et al. (2014) reported the susceptibility of mycobacteria (sensitive and resistant) to naphthoquinones, mainly plumbagin, with MIC between 0.25 and 16 \( \mu \text{g/mL} \). Thus, both highlight the potential of naphthoquinones in the search for new anti-TB drugs. Our research group has developed several studies with a focus on new antimicrobial agents and, although other studies have reported the activity of other naphthoquinone derivatives, including for resistant strains, their mechanism of action is still uncertain (Coelho et al., 2010; Jardim et al., 2015).

Based on the analysis of the structure-activity relationship, the compound 3, which has a tetrahydrofuran radical and anti-trypanosome activity previously described (De Moura et al., 2001), showed MIC = 54.8 \( \mu \text{M} \) against the three *M. tuberculosis* strains, while the compound 2, which contains a tetrahydropyran radical, showed MIC between 103.3 and 206.6 \( \mu \text{M} \). Besides showing a better antimycobacterial activity, the compound 3 has also shown reduced cytotoxicity (IC\(_{50}\) > 877 \( \mu \text{M} \)) compared with 2 (IC\(_{50}\) = 285 \( \mu \text{M} \)), and both showed none mutagenic or tumorigenic risks (Table 3).

When we analyzed the compounds with nitrogen (5 and 6), it was noticed that phenylamine radical in the compound 6 has decreased the activity for the susceptible and INHR strains, while was able to a threefold increase the activity of this naphthoquinone for RMP\(_{R}\) strain, compared with compound 5, which has the amine group (Table 2). The activity of naphthoquinones with nitrogenous radicals also has been described against fungi, gram positive and negative bacteria (Riffel et al., 2002; Rahmoun et al., 2013).

Among the rifampicin-resistant *M. tuberculosis*, about 35% have the mutation H526Y (Molodtsov et al., 2017) and, considering that compound 6 was active against the RMP\(_{R}\) strain, we can infer that there is probably no cross-resistance between this compound and RMP, what was also evidenced in the docking analysis (Molodtsov et al., 2017). Moreover, due to the lower binding energies of the compound 6 when compared to the binding energies of RIF in RRDR, the mutation seems to favor the binding between the naphthoquinone 6 and the RRDR (Figure 1).

Furthermore, among the naphthoquinone derivatives evaluated, the compound 5 was the most active for the INHR strain (MIC = 36.1 \( \mu \text{M} \)), which has a mutation in the katG gene (S315T). This result evidences the absence of cross-resistance of this compound with INH, especially in strains that have this mutation.

According to the results of *in silico* pharmacokinetics, the naphthoquinone derivatives have inhibitory potential in some human CYP450 isofroms. It is known that the electron transfer chain is directly related with activity of enzymes, such as NADH, transferring electrons from lipophilic redox carriers. In this context, the importance of this biosynthetic route as a target in the search for new antimicrobials has been highlighted (Black et al., 2014) and, considering the results obtained in this study, the naphthoquinones could act as other quinones previously described, in the transfer chain of electrons (Heikal et al., 2016).

**CONCLUSION**

Considering the potential of quinones as a source of new antimicrobial agents and their biological activities already reported, this set of findings confirm this hypothesis and demonstrate that, naphthoquinones derivatives could be scaffolds for the development of new anti-TB drugs.

**AUTHOR CONTRIBUTIONS**

PH, DR, and PdS designed the study. KDM, PC, KDR, TC, and MP contributed with compounds synthesis. PH, LF, and DR performed the experiments. PH, DR, PdS, and KDM analyzed the data and wrote the manuscript. All authors approved the version to be published.

**ACKNOWLEDGMENTS**

This work was supported by National Council for Technological and Scientific Development (CNPq) and Coordination for the Improvement of Higher Education Personnel (CAPES).
of tetrahydropyridines as drug efflux inhibitors in *Escherichia coli*. *Int. J. Antimicrob. Agents* 49, 308–314. doi: 10.1016/j.ijantimicag.2016.11.024

Snewin, V. A., Gares, M. P., Gaora, P. Ó., Hasan, Z., Brown, I. N., and Young, D. B. (1999). Assessment of immunity to mycobacterial infection with luciferase reporter constructs. *Infect. Immun.* 67, 4586–4593.

Stefanova, T. (2014). Quality control and safety assessment of RCG vaccines in the post-genomic era. *Biotechnol. Biotechnol. Equip.* 28, 387–391. doi: 10.1080/13102818.2014.927200

Uc-Cachón, A. H., Borges-Argáez, R., Said-Fernández, S., Vargas-Villarreal, J., González-Salazar, F., Méndez-González, M., et al. (2014). Naphthoquinones isolated from *Diospyros anisandra* exhibit potent activity against pan-resistant first-line drugs *Mycobacterium tuberculosis* strains. *Pulm. Pharmacol. Ther.* 27, 114–120. doi: 10.1016/j.pupt.2013.08.001

WHO (2017). *WHO Global Tuberculosis Report 2017*. Geneva: World Health Organization.

Woods, G. L., Brown-Elliot, B. A., Conville, P. S., Desmond, E. P., Hall, G. S., and Lin, G. (2011). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard-second edition. *Clin. Lab. Stand. Inst.* 26, 1–61. doi: 10.1306/E4FD4657-1732-11D7-8645000102C1865D

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Halicki, Ferreira, De Moura, Carneiro, Del Rio, Carvalho, Pinto, da Silva and Ramos. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.